The main domestic manufacturers of acotinib/acalabrutinib reveal their secrets

Acalabrutinib/The original drug Acalabrutinib has been officially launched in China, and the main manufacturer behind it is the high-profile AstraZeneca (affiliated with AstraZeneca AB of Sweden). AstraZeneca, as the world's leading biopharmaceutical giant, has been committed to the research and development, production and sales of innovative drugs, aiming to provide diversified and efficient treatment options for patients around the world.

In the development and production of acotinib, AstraZeneca has fully demonstrated its profound R&D heritage and innovation capabilities. This drug, as a highly selective BTK inhibitor, effectively inhibits the activation of the primary antibody signaling pathway on the surface of B cells, bringing a new treatment strategy to patients with B-cell lymphomas, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). It is worth mentioning that acotinib received its first approval and was successfully launched in China on May 26, 2023. This important moment not only marks the further consolidation and expansion of AstraZeneca’s business in the Chinese market, but also means that Chinese patients will have access to more advanced treatment options.

AstraZeneca has an extensive presence in the Chinese market and its influence cannot be underestimated. In addition to acotinib, AstraZeneca has also successfully launched a number of innovative drugs in China. The launch of these drugs has greatly enriched China's pharmaceutical market and provided more comprehensive treatment options for patients. Currently, the original drug of acotinib capsules on the domestic market is 100mg*56 capsules, with a market price of approximately more than 40,000 yuan. Although the drug has been included in Category B medical insurance, the reimbursement policy is limited to patients who meet the indications.